Past event: Oligonucleotide Discovery and Delivery Conference

Driving The Advancement Of Oligonucleotide Discovery And Target Specificity

This year the 3rd annual Oligonucleotide Therapeutics and Delivery conference will showcase recent advances in oligonucleotide development, regulatory requirements and CMC considerations, strategies to enhance oligonucleotide discovery and targeting and optimised delivery techniques for oligonucleotide-based therapies, in the hope to continue to drive forward the field of oligonucleotide drug development. Join us on the 11-12 September.

The only event that will:

Showcase new representation and insights from the following big pharma companies, with a high level agenda focussing on driving industry advancement, whilst also offering benchmarking and networking opportunities for leading figures in the industry.
  • Eli lilly
  • Moderna
  • BioNTech
  • Alnylam Pharmaceuticals
  • GSK
  • Merck
  • Servier
  • AstraZeneca
  • Roche
  • Bayer

What's different this year:

This year the conference will be chaired by two leaders in the field of oligonucleotide therapeutics and delivery: Joseph R. Martinelli, Executive Director, Genetic Medicine, Eli Lilly and Company & Edward Hennessy, Senior Director, Discovery Chemistry, Moderna.

Benefits of Attending

  • Examine recent developments in CMC practices and key considerations for oligonucleotide manufacturing, with insights from leading industry experts, including Roche,  GSK and many more
  • Enhance your knowledge of the latest innovations in early stage discovery, with key case studies from leading biotechs including
  • Arthex Bio, Altamira Therapeutics and Rnatics
  • Engage in current trends and solutions for optimising delivery techniques and target specificity beyond the liver
  • Explore developments in new novel applications of ASOs and expand on current discovery chemistry techniques

Who should attend

Pharma and Biotech Directors, Managers and Heads of Departments of:
  • RNA
  • Genetic Medicine
  • Oligonucleotide Discovery
  • RNA Discovery
  • New Modalities
  • RNA Biology
  • RNA Formulation and Delivery
  • Targeted Delivery
  • Clinical Development
  • Pre-Clinical Development
  • Oligonucleotide Chemistry
  • Drug Discovery
  • Target Discovery
  • Medicinal Chemistry
  • RNA Development
  • RNA Vaccines
  • RNA Biochemistry

Featured Speakers

  • Covadonga Paneda, Chief Development Officer, Altamira Therapeutics
  • David Tew, Senior Scientific Director, GSK
  • Dhiman Ghosh, Lab Head/Senior Principal Scientist, Sanofi
  • Edward Hennessy, Senior Director, Discovery Chemistry, Moderna
  • Ekkehard Leberer, Scientific Advisor, NEUWAY Pharma
  • Florian Mann, Lab Head Drug Targeting & Vectors, Bayer AG Pharmaceuticals
  • Joseph Martinelli, Executive Director, Eli Lilly
  • Judith Walker, Chief Medical Officer, Arthex Biotech
  • Kaushik Thanki, Director Early-Stage Formulation Process Development, BioNTech SE
  • Lee Klein, Principal Scientist, Merck & Co., Inc
  • Michael Keller, Expert Scientist, Roche
  • Nagy Habib, Head of HBP Surgery, Co-Founder, Imperial College
  • Paul Nioi, Vice President, Discovery and Translational Research, Alnylam
  • Thierry Dorval, Head of Data Sciences & Data Management, Institut de Recherches Servier
  • Thomas Frischmuth, CEO, rnatics GmbH
  • Yaniv Erlich, CEO, Eleven Therapeutics

Please fill in your name and email to receive the Conference Agenda of this event.

Venue

Hilton London Kensington
179-199 Holland Park Ave, Kensington, W11 4UL
London, UK


Event details
Organizer : SAE Media Group
Event type : Conference
Reference : ASDE-24312